目的 探討黃芪注射液聯(lián)合重組人干擾素α2a栓治療宮頸癌前病變的臨床療效。方法 選取2012年3月-2015年6月邢臺(tái)市人民醫(yī)院婦產(chǎn)新生兒院區(qū)收治的宮頸癌前病變患者90例，按就診順序分為對(duì)照組與治療組，每組各45例。對(duì)照組患者月經(jīng)干凈后3～4 d，睡前重組人干擾素α2a栓放入陰道后穹窿，1枚/次，隔日1次，經(jīng)期停藥，用藥45次。治療組在對(duì)照組的基礎(chǔ)上靜脈滴注黃芪注射液，10～20 mL/次，1次/d，經(jīng)期停藥，治療45 d。評(píng)價(jià)兩組臨床療效，比較兩組CD3⁺、CD4⁺、CD8⁺及NK細(xì)胞活性的變化，觀察治療前后患者陰道清潔度的變化。結(jié)果 治療后，對(duì)照組和治療組總有效率分別為71.11%和88.89%，兩組總有效率比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組CD3⁺、CD4⁺、CD8⁺和NK水平均顯著升高（P<0.05）；且治療組這些觀察指標(biāo)的升高程度優(yōu)于對(duì)照組（P<0.05）。治療后，兩組Ⅰ～Ⅱ級(jí)陰道清潔度例數(shù)明顯升高，Ⅲ～Ⅳ級(jí)例數(shù)明顯降低，同組治療前后差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組上述陰道清潔度例數(shù)變化比對(duì)照組更明顯（P<0.05）。結(jié)論 黃芪注射液聯(lián)合重組人干擾素α2a栓治療宮頸癌前病變能夠顯著改善患者機(jī)體免疫功能和提升陰道清潔度，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To explore the clinical effect of Huangqi Injection combined with Recombinant Human Interferon α2a Vaginal Suppository in treatment of cervical precancerous lesions. Methods Patients (90 cases) with cervical precancerous lesions in Maternity and Newborn Hospital Section of Xingtai People's Hospital from March 2012 to June 2015 were divided into the control and treatment groups according to the visiting sequence, and each group had 45 cases. After menstruation was clean for 3-4 d, the patients in the control group were given Recombinant Human Interferon α2a Vaginal Suppository at posterior vaginal fornix before bedtime every other day for 45 times medication, 1 suppository/time, menstrual withdrawal. The patients in the treatment group were iv administered with Huangqi Injection on the basis of the control group, and treated for 45 d, 10-20 mL/time, once daily, menstrual withdrawal. After treatment, the clinical efficacy was evaluated, CD3⁺, CD4⁺, CD8⁺, and NK in two groups were compared, and the change of vaginal cleanliness was observed. Results After treatment, the clinical efficacy in the control and treatment group were 71.11% and 88.89%, respectively, and there were differences between two groups (P<0.05). After treatment, CD3⁺, CD4⁺, CD8⁺, and NK levels in two groups were significantly increased (P<0.05), And compared with the control group, these observation indexes in treatment group were better than those in the control group (P<0.05). After treatment, the cases of Ⅰ-Ⅱ degree vaginal cleanliness in two groups was significantly increased, the cases of Ⅲ-Ⅳ degree was decreased, and the difference was statistically significant in the same group (P<0.05). And the change of vaginal cleanliness cases in the treatment group was more significant than that in the control group, with significant difference between two groups (P<0.05). Conclusion Huangqi Injection combined with Recombinant Human Interferon α2a Vaginal Suppositories can significantly improve the immune function and enhance vaginal cleanliness in treatment of cervical precancerous lesions, which has a certain clinical application value.